CSIMarket Company Name, Ticker, Industry, else..
 
Cidara Therapeutics Inc   (NASDAQ: CDTX)

Select the Financial Report: Select the Period:

Description of Cidara Therapeutics Inc's Business Segments
Cidara Therapeutics Inc. is a biopharmaceutical company dedicated to addressing significant unmet medical needs in the fields of infectious diseases through the research, development, and commercialization of novel anti-infectives. The company operates primarily in two key segments: antifungal therapeutics and antibacterial therapeutics.

Segments

1. Antifungal Therapeutics:
Cidara’s primary focus lies in the development of innovative antifungal therapies aimed at combating serious fungal infections. This segment involves advanced research and pharmacological studies to create effective treatments for conditions like candidemia and invasive aspergillosis. The company is investigating new agents that target resistant strains of fungi, which have become a growing concern in clinical settings.

2. Antibacterial Therapeutics:
With the rise in multi-drug resistant bacterial infections, Cidara is also investing in the antibacterial segment. This area focuses on developing new drugs to treat infections caused by multi-drug-resistant Gram-negative bacteria, addressing a critical gap in current antibacterial therapies. By targeting resistant pathogens, the company aims to enhance treatment outcomes in patients affected by severe bacterial infections.

Products

1. Rezafungin:
Rezafungin is Cidaras lead product and represents a novel class of antifungal agents. It is currently under investigation as a once-weekly intravenous treatment for serious invasive fungal infections. Rezafungins unique mechanism of action distinguishes it from traditional antifungal therapies, particularly by its potential to overcome existing limitations such as drug resistance and side effects associated with current treatments. Its development is pivotal in providing a new therapeutic option for patients suffering from life-threatening fungal infections.

Services

1. Drug Development:
Cidara Therapeutics leverages its expertise in drug development to offer a wide range of services encompassing preclinical research, clinical trial management, regulatory submissions, and large-scale manufacturing. The company collaborates with external partners to navigate the complex landscape of drug development, ensuring successful progression from concept through to market.

2. Research Collaborations:
The company actively seeks partnerships with academic institutions, other biopharmaceutical companies, and government agencies to enhance its research capabilities. These collaborations aim to pool resources and share insights, accelerating the development of groundbreaking treatments for infectious diseases.

3. Clinical Trials:
Cidara conducts rigorous clinical trials to assess the safety and efficacy of its therapeutic candidates. By working in conjunction with leading medical centers and healthcare professionals, the company gathers vital data that informs its clinical development strategies and regulatory submissions.

4. Commercialization:
Beyond discovery and development, Cidara is committed to the successful commercialization of its products. The company focuses on establishing robust sales and marketing strategies to ensure that its innovative therapies reach patients and healthcare providers globally. This includes efforts to build awareness of its drugs, facilitate distribution, and maintain accessibility in diverse healthcare settings.

Conclusion

In summary, Cidara Therapeutics Inc. stands at the forefront of combating infectious diseases with a dual focus on antifungal and antibacterial therapeutics. With innovative products like Rezafungin and a commitment to comprehensive drug development services, research partnerships, clinical trial execution, and strategic commercialization, Cidara is poised to make significant contributions to the treatment landscape in infectious diseases, especially against the backdrop of rising drug resistance.

Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.



Annual Report on Cidara Therapeutics Inc Divisions, Sales by Country

 
Reportable Segment   Reportable Segment Segment contribution to total sales 100 % of total Revenue
Related Party Janssen Pharmaceuticals Inc Collaborative Arrangement Transaction with Party to Collaborative Arrangement   Related Party Janssen Pharmaceuticals Inc Collaborative Arrangement Transaction with Party to Collaborative Arrangement Segment contribution to total sales 100 % of total Revenue
Related Party Janssen Pharmaceuticals Inc Research and Development Services Transferred Over Time Collaborative Arrangement Transaction with Party to Collaborative Arrangement   Related Party Janssen Pharmaceuticals Inc Research and Development Services Transferred Over Time Collaborative Arrangement Transaction with Party to Collaborative Arrangement Segment contribution to total sales 99.84 % of total Revenue
Related Party Janssen Pharmaceuticals Inc Clinical Supply Services Transferred Over Time Collaborative Arrangement Transaction with Party to Collaborative Arrangement   Related Party Janssen Pharmaceuticals Inc Clinical Supply Services Transferred Over Time Collaborative Arrangement Transaction with Party to Collaborative Arrangement Segment contribution to total sales 0.16 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Mundipharma   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Mundipharma Segment contribution to total sales 2249.49 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Melinta Therapeutics Inc   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Melinta Therapeutics Inc Segment contribution to total sales 45.65 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Royalty Revenue Melinta Therapeutics Inc   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Royalty Revenue Melinta Therapeutics Inc Segment contribution to total sales 7.84 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Rezafungin Assets including Sale of IP and Inventory Mundipharma   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Rezafungin Assets including Sale of IP and Inventory Mundipharma Segment contribution to total sales 1633.96 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time License of Intellectual Property - upon milestones achieved Mundipharma   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time License of Intellectual Property - upon milestones achieved Mundipharma Segment contribution to total sales 63.76 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Product Revenue Mundipharma   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Product Revenue Mundipharma Segment contribution to total sales 221.65 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Royalty Revenue Mundipharma   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Royalty Revenue Mundipharma Segment contribution to total sales 2.9 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Royalty Revenue Melinta Therapeutics Inc   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Royalty Revenue Melinta Therapeutics Inc Segment contribution to total sales 9.8 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Research and Development Services Mundipharma   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Research and Development Services Mundipharma Segment contribution to total sales 305.49 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Research and Development Services Melinta Therapeutics Inc   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Research and Development Services Melinta Therapeutics Inc Segment contribution to total sales 35.84 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Clinical Supply Services Mundipharma   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Clinical Supply Services Mundipharma Segment contribution to total sales 13.73 % of total Revenue
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Transition Services Mundipharma   Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Transition Services Mundipharma Segment contribution to total sales 8 % of total Revenue


Twelve months ended 2024
CDTX s Annual Revenue by Geography and Business Segments Sales
(in millions $)		 %
(of total Sales)
Total 1.28 100 %
Reportable Segment 1.28 100 %
Related Party Janssen Pharmaceuticals Inc Collaborative Arrangement Transaction with Party to Collaborative Arrangement 1.28 100 %
Related Party Janssen Pharmaceuticals Inc Research and Development Services Transferred Over Time Collaborative Arrangement Transaction with Party to Collaborative Arrangement 1.27 99.84 %
Related Party Janssen Pharmaceuticals Inc Clinical Supply Services Transferred Over Time Collaborative Arrangement Transaction with Party to Collaborative Arrangement 0.00 0.16 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Mundipharma 28.68 2249.49 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Melinta Therapeutics Inc 0.58 45.65 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Royalty Revenue Melinta Therapeutics Inc 0.10 7.84 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Rezafungin Assets including Sale of IP and Inventory Mundipharma 20.83 1633.96 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time License of Intellectual Property - upon milestones achieved Mundipharma 0.81 63.76 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Product Revenue Mundipharma 2.83 221.65 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Royalty Revenue Mundipharma 0.04 2.9 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Royalty Revenue Melinta Therapeutics Inc 0.13 9.8 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Research and Development Services Mundipharma 3.90 305.49 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Research and Development Services Melinta Therapeutics Inc 0.46 35.84 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Clinical Supply Services Mundipharma 0.18 13.73 %
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Transition Services Mundipharma 0.10 8 %


Twelve months ended 2024
CDTX s Annual Income by Country and Business Segments Income
(in millions $)		 %
(Profit Margin)
Total -169.83 -

Twelve months ended 2024
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Reportable Segment -94.52 % -
Related Party Janssen Pharmaceuticals Inc Collaborative Arrangement Transaction with Party to Collaborative Arrangement -94.52 % -
Related Party Janssen Pharmaceuticals Inc Research and Development Services Transferred Over Time Collaborative Arrangement Transaction with Party to Collaborative Arrangement -93.3 % -
Related Party Janssen Pharmaceuticals Inc Clinical Supply Services Transferred Over Time Collaborative Arrangement Transaction with Party to Collaborative Arrangement -99.9 % -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Mundipharma 48.7 % -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Melinta Therapeutics Inc -97.27 % -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Royalty Revenue Melinta Therapeutics Inc -50 % -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time License of Intellectual Property - upon milestones achieved Mundipharma -75 % -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Product Revenue Mundipharma -1.43 % -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Royalty Revenue Melinta Therapeutics Inc -25.6 % -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Research and Development Services Mundipharma -68.34 % -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Research and Development Services Melinta Therapeutics Inc -81.28 % -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred Over Time Clinical Supply Services Mundipharma -79.17 % -
Related Party Janssen Pharmaceuticals Inc License of Intellectual Property - upon milestones achieved Transferred at Point in Time Collaborative Arrangement Transaction with Party to Collaborative Arrangement - -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time License of Intellectual Property - upon milestones achieved Melinta Therapeutics Inc - -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Clinical Drug Supply Mundipharma - -
Rezafungin Discontinued Operations Disposed of by Sale Related Party Collaborative Arrangement Transaction with Party to Collaborative Arrangement Transferred at Point in Time Product Revenue Melinta Therapeutics Inc - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.